SecBot SecBot
Biotech Drug Report Generated Nov 13, 2026

MYQORZO

CYTK·Cytokinetics, Incorporated
BULLISH
Drug Impact Rating7/10
Trial phase
Approved
Time to market
Already approved and commercializing in the U.S. (since December 2025) and Canada (October 2026). A label expansion decision from the FDA is expected November 14, 2026. A supplemental NDA for non-obstructive HCM is planned for submission in Q4 2026, with potential approval in 2027. EU submission is planned for early 2027.
Why 7/10
The next hard, dated catalyst is the FDA PDUFA decision on November 14, 2026 (tomorrow) for the supplemental NDA based on the MAPLE-HCM trial, which could expand the label for aficamten in obstructive HCM. Since the drug is already approved and generating revenue, this is a label-expansion binary rather than a make-or-break event, but it is the company's lead asset and the catalyst is imminent, supporting a score of 7.
Actionable Insight BULLISH

The FDA decision on the MAPLE-HCM sNDA is due tomorrow, November 14, 2026. An approval would expand the label to include data showing aficamten's superiority over metoprolol, potentially strengthening the drug's positioning against standard-of-care beta blockers and BMS's Camzyos. A Complete Response Letter would be a negative surprise given the positive Phase 3 data. Separately, the supplemental NDA for non-obstructive HCM (ACACIA-HCM) is expected to be submitted in Q4 2026, which could be the next major catalyst.

Price Chart

Loading chart...

Executive Summary

MYQORZO (aficamten) is Cytokinetics' first approved drug, a cardiac myosin inhibitor for hypertrophic cardiomyopathy (HCM). It received FDA approval in December 2025 for symptomatic obstructive HCM and Health Canada approval in October 2026. The drug generated $44.5 million in Q3 2026 net revenue (76% sequential growth). The next major catalyst is a PDUFA decision on November 14, 2026 for a supplemental NDA based on the MAPLE-HCM trial, which showed aficamten's superiority over the standard beta blocker metoprolol. Separately, the Phase 3 ACACIA-HCM trial in non-obstructive HCM (a condition with no approved treatments) met both primary endpoints, and a supplemental NDA submission is expected in Q4 2026. Analyst consensus is strongly bullish with a mean price target of $109.42, implying roughly 95% upside from the current ~$56 share price.

How It Works

Aficamten is a cardiac myosin inhibitor. It works by reducing the force of contraction of the heart muscle. In hypertrophic cardiomyopathy, the heart muscle becomes abnormally thick, making it harder for the heart to pump blood. By inhibiting the cardiac myosin protein (the motor that drives heart muscle contraction), aficamten reduces excessive contraction, improves blood flow, and relieves symptoms like shortness of breath and chest pain.

Trial Status

MYQORZO is FDA-approved for symptomatic obstructive HCM (based on SEQUOIA-HCM Phase 3 trial) and Health Canada-approved. The MAPLE-HCM Phase 3 trial (aficamten vs. metoprolol in oHCM) met its primary endpoint and supports a pending sNDA with a PDUFA date of November 14, 2026. The ACACIA-HCM Phase 3 trial in non-obstructive HCM met both dual primary endpoints, with full results presented at ESC Congress 2026 and additional data at HFSA 2026 and HCMS/AHA 2026. A real-world study (ASPEN-HCM) launched in September 2026.

The Two-Sided Case

▲ Bull Case6
MYQORZO is already generating meaningful revenue: $44.5 million in Q3 2026, a 76% sequential increase, with nearly 1,100 U.S. prescribers and over 2,800 patients dispensed.
The PDUFA date for the MAPLE-HCM sNDA is November 14, 2026 (tomorrow). MAPLE-HCM showed aficamten was superior to the standard-of-care beta blocker metoprolol, which could strengthen the drug's label and physician adoption.
The Phase 3 ACACIA-HCM trial in non-obstructive HCM met both dual primary endpoints. There are currently no approved treatments for nHCM, representing a large untapped market opportunity. A supplemental NDA is expected in Q4 2026.
Analyst consensus is strongly bullish: 25 analysts rate it Buy/Strong Buy (mean target $109.42, implying ~95% upside from ~$56), with only 3 Holds and zero Sells.
The company has a strong cash position of ~$1.6 billion, providing runway for commercial expansion and pipeline development.
Health Canada approved MYQORZO in October 2026, and a Type II Variation submission in the EU is planned for early 2027, opening additional geographic markets.
▼ Bear Case5
Competition from Bristol Myers Squibb's Camzyos (mavacamten), the first-in-class cardiac myosin inhibitor approved for oHCM, could limit MYQORZO's market share and pricing power.
The stock trades at roughly half the mean analyst price target of $109.42, suggesting the market is already discounting significant commercial or regulatory risk.
Insider selling has been consistent: CEO Robert Blum, EVP Fady Malik, and director B. Lynne Parshall have all sold shares in recent months under 10b5-1 plans, which may signal that internal expectations are tempered.
FMR LLC (Fidelity) trimmed its CYTK position by 55.8% in Q3 2026, and Capital International Investors nearly exited, suggesting some large holders are reducing exposure.
The ACACIA-HCM full data release in August 2026 caused the stock to trade lower, indicating the market may have already priced in the nHCM opportunity.

Upcoming Catalysts

  • FDA PDUFA decision on MAPLE-HCM sNDA: November 14, 2026 (label expansion for oHCM)
  • Supplemental NDA submission for non-obstructive HCM (ACACIA-HCM): expected Q4 2026
  • Type II Variation submission in the European Union: expected early 2027

Source Filing

The SecBot filing or press-release report that triggered this drug report:

CYTOKINETICS INC CLUSTER CYTK ·Originating report

Sources · 8

Hover a chip for the title
1 markets.businessinsider.com2 msn.com3 statnews.com4 healio.com5 streetinsider.com6 sec.gov7 streetinsider.com8 fiercepharma.com